196 related articles for article (PubMed ID: 37231827)
1. Mechanistic and Clinical Comparison of the Erythropoietic Effects of SGLT2 Inhibitors and Prolyl Hydroxylase Inhibitors in Patients with Chronic Kidney Disease and Renal Anemia.
Packer M
Am J Nephrol; 2024; 55(2):255-259. PubMed ID: 37231827
[TBL] [Abstract][Full Text] [Related]
2. Zinc Supplementation Enhances the Hematopoietic Activity of Erythropoiesis-Stimulating Agents but Not Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors.
Takahashi A
Nutrients; 2024 Feb; 16(4):. PubMed ID: 38398842
[TBL] [Abstract][Full Text] [Related]
3. The drug-specific properties of hypoxia-inducible factor-prolyl hydroxylase inhibitors in mice reveal a significant contribution of the kidney compared to the liver to erythropoietin induction.
Nakai T; Saigusa D; Kato K; Fukuuchi T; Koshiba S; Yamamoto M; Suzuki N
Life Sci; 2024 Jun; 346():122641. PubMed ID: 38614299
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular safety of current and emerging drugs to treat anaemia in chronic kidney disease: a safety review.
Locatelli F; Paoletti E; Del Vecchio L
Expert Opin Drug Saf; 2023; 22(12):1179-1191. PubMed ID: 38111209
[TBL] [Abstract][Full Text] [Related]
5. [Clinical application and future perspectives of HIF-PH inhibitors].
Nangaku M
Nihon Yakurigaku Zasshi; 2024; 159(3):157-159. PubMed ID: 38692879
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Novel and Potent Prolyl Hydroxylase Domain-Containing Protein (PHD) Inhibitors for The Treatment of Anemia.
Xu J; Ding X; Fu Y; Meng Q; Wang L; Zhang M; Xu C; Chen S; Aliper A; Ren F; Zhavoronkov A; Ding X
J Med Chem; 2024 Jan; 67(2):1393-1405. PubMed ID: 38189253
[TBL] [Abstract][Full Text] [Related]
7. Consensus commentary and position of the Italian Society of Nephrology on KDIGO controversies conference on novel anemia therapies in chronic kidney disease.
Locatelli F; Del Vecchio L; Esposito C; Gesualdo L; Grandaliano G; Ravera M; ; Minutolo R
J Nephrol; 2024 Apr; 37(3):753-767. PubMed ID: 38705934
[TBL] [Abstract][Full Text] [Related]
8. Discovery of DS44470011: An oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of renal anemia.
Fukuda T; Kuribayashi T; Takano R; Sasaki K; Tsuji T; Niitsu Y; Ishii K; Hashimoto M; Baba D; Ito S; Tanaka N
Bioorg Med Chem Lett; 2024 Aug; 108():129799. PubMed ID: 38754564
[TBL] [Abstract][Full Text] [Related]
9. [New Therapeutic Strategies in the Treatment of CKD Anemia: Hypoxia-Induced Factor Prolyl-Hydroxylase Inhibitors].
Taurisano M; Protopapa P; Barbarini S; Mancini A; Cortese C; Napoli M
G Ital Nefrol; 2023 Oct; 40(5):. PubMed ID: 38010250
[TBL] [Abstract][Full Text] [Related]
10. Effect of SGLT2 inhibitors on anemia and their possible clinical implications.
Cases A; Cigarrán S; Luis Górriz J; Nuñez J
Nefrologia (Engl Ed); 2024; 44(2):165-172. PubMed ID: 38604895
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of enhanced renal and hepatic erythropoietin synthesis by sodium-glucose cotransporter 2 inhibitors.
Packer M
Eur Heart J; 2023 Dec; 44(48):5027-5035. PubMed ID: 37086098
[TBL] [Abstract][Full Text] [Related]
12. Mutual Antagonism of Hypoxia-Inducible Factor Isoforms in Cardiac, Vascular, and Renal Disorders.
Packer M
JACC Basic Transl Sci; 2020 Sep; 5(9):961-968. PubMed ID: 33015417
[TBL] [Abstract][Full Text] [Related]
13. A Prospective Randomized Controlled Clinical Study to Investigate the Efficacy and Safety of Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors in Non-Dialysis Patients with Chronic Heart Failure and Renal Anemia Switched from Continuous Erythropoietin Receptor Activator Treatment.
Sezai A; Abe M; Maruyama T; Taoka M; Sekino H; Tanaka M
J Clin Med; 2024 May; 13(10):. PubMed ID: 38792306
[No Abstract] [Full Text] [Related]
14. Mechanisms Leading to Differential Hypoxia-Inducible Factor Signaling in the Diabetic Kidney: Modulation by SGLT2 Inhibitors and Hypoxia Mimetics.
Packer M
Am J Kidney Dis; 2021 Feb; 77(2):280-286. PubMed ID: 32711072
[TBL] [Abstract][Full Text] [Related]
15. Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
Ku E; Del Vecchio L; Eckardt KU; Haase VH; Johansen KL; Nangaku M; Tangri N; Waikar SS; Więcek A; Cheung M; Jadoul M; Winkelmayer WC; Wheeler DC;
Kidney Int; 2023 Oct; 104(4):655-680. PubMed ID: 37236424
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Characterization of Vadadustat (AKB-6548), an Oral Small Molecule Hypoxia-Inducible Factor Prolyl-4-Hydroxylase Inhibitor, for the Potential Treatment of Renal Anemia.
Zuk A; Si Z; Loi S; Bommegowda S; Hoivik D; Danthi S; Molnar G; Csizmadia V; Rabinowitz M
J Pharmacol Exp Ther; 2022 Oct; 383(1):11-24. PubMed ID: 35926869
[TBL] [Abstract][Full Text] [Related]
17. Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors.
Sugahara M; Tanaka T; Nangaku M
Pharmacol Ther; 2022 Nov; 239():108272. PubMed ID: 36031160
[TBL] [Abstract][Full Text] [Related]
18. The role of hypoxia in chronic kidney disease: a nuanced perspective.
Faivre A; de Seigneux S
Curr Opin Nephrol Hypertens; 2024 Jul; 33(4):414-419. PubMed ID: 38597413
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: A meta-analysis including 13,146 patients.
Chen H; Cheng Q; Wang J; Zhao X; Zhu S
J Clin Pharm Ther; 2021 Aug; 46(4):999-1009. PubMed ID: 33615523
[TBL] [Abstract][Full Text] [Related]
20. Prolyl Hydroxylase Inhibitors: a New Opportunity in Renal and Myocardial Protection.
Requena-Ibáñez JA; Santos-Gallego CG; Rodriguez-Cordero A; Zafar MU; Badimon JJ
Cardiovasc Drugs Ther; 2022 Dec; 36(6):1187-1196. PubMed ID: 34533692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
